Global Peripheral T-Cell Lymphoma (PTCL) Report 2018: Market Insights, Epidemiology and Market Forecast 2016-2027 Featuring AB Science, Celgene, CerRx & Onxeo S.A.
DUBLIN, Jan. 2, 2018
DUBLIN, Jan. 2, 2018 /PRNewswire/ --
The "Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Peripheral T-Cell Lymphoma (PTCL) in the United States, the EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Peripheral T-Cell Lymphoma (PTCL) from 2016 to 2027; segmented by the seven major markets. The Report also covers the current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Peripheral T-Cell Lymphoma (PTCL) - Disease Understanding and Treatment Algorithm
Peripheral T-cell lymphoma (PTCL) is a group of rare and usually aggressive (fast-growing) Non-Hodgkin's Lymphomas (NHL) that develops from mature T-cells. Peripheral T-Cell Lymphoma (PTCL) comprises about 10-15% of all NHL cases in United States [Skarbnik, A.P. et.al.]
The Peripheral T cell lymphomas was classified by WHO in 2008 and updated in 2016. According to this, the Peripheral T Cell Lymphomas can be broadly classified according to the site of origin of the malignant T cell in the body - Nodal, Extranodal, Cutaneous and Leukemic. Most of the subtypes are rare and mainly 4 subtypes of PTCL- Peripheral T-Cell Lymphoma not otherwise specified (PTCL-NOS), Anaplastic Large-Cell Lymphoma (ALCL), Nasal NK/T-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma (AITL) accounts for about 75% of the PTCL cases.
Peripheral T-Cell Lymphoma (PTCL) is also a common and treatable cause of infertility. It causes missed or irregular menstrual periods which can lead to:
- Infertility (inability to get pregnant)
- Development of cysts (small fluid-filled sacs) in the ovaries
The Peripheral T-Cell Lymphoma (PTCL) market report gives a thorough understanding of the Peripheral T-Cell Lymphoma (PTCL) by including details, such as disease definition, subtypes, staging, causes, symptoms, pathophysiology, diagnosis and treatment. It also provides treatment algorithms and treatment guidelines for Peripheral T-Cell Lymphoma (PTCL) in the US, Europe, and Japan.
Peripheral T-Cell Lymphoma (PTCL) Epidemiology
The Peripheral T-Cell Lymphoma (PTCL) epidemiology division provides the insights about historical and current patient pool and forecasted trend for every 7 major market country. The report helps to recognize the causes of the current and forecasted trends by analyzing numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of Peripheral T-Cell Lymphoma (PTCL) associated with Diagnosed and Treatable Cases of Peripheral T-Cell Lymphoma (PTCL), Stage Wise Cases of Peripheral T-Cell Lymphoma (PTCL) and Common Types of Peripheral T-Cell Lymphoma (PTCL)] scenario of Peripheral T-Cell Lymphoma (PTCL) in the 7MM covering the United States, the EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
The incident population of Peripheral T-Cell Lymphoma (PTCL) in the 7MM countries is expected to change during the study period i.e. 2016-2027.
The incident cases of Peripheral T Cell Lymphoma (PTCL) represent the Non-Hodgkin's Lymphoma patient pool who are diagnosed with PTCL. In United States with the highest number of incident Peripheral T-Cell Lymphoma (PTCL) cases accounts for about 10% of all Non-Hodgkin's Lymphoma cases. There were a total of 7,258 incident cases in 2016. In Europe, very limited number of studies are available for Peripheral T-Cell lymphoma as the indication is very rare. Based on the secondary research and KOLs, it is found that Peripheral T-Cell lymphoma (PTCL) accounted for about 8-15% of total NHL cases in EU5.
This research estimates that the total number of incident Peripheral T-Cell Lymphoma (PTCL) cases is expected to increase in 2027.
Peripheral T-Cell Lymphoma (PTCL) Drug Chapters
This segment of the Peripheral T-Cell Lymphoma (PTCL) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each of the included drug and the latest news and press releases.
The current therapeutic landscape of Peripheral T-Cell Lymphoma (PTCL) includes the detailed chapters of upcoming therapies, such as Masitinib (AB Science), Fenretinide (CerRx) and other effective emerging therapeutic products; which are expected to lead to a significant change in the market size during the forecast period [2018-2027].
Peripheral T-Cell Lymphoma (PTCL) Market Outlook
The Peripheral T-Cell Lymphoma (PTCL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and views of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at the first sight.
According to this research, the market size of Peripheral T-Cell Lymphoma (PTCL) in the seven major markets is expected to change by 2027. Current available products like Onxeo's Beleodaq; Celgene's Istodax and many others are occupying the Peripheral T-Cell Lymphoma (PTCL) market. The market for Peripheral T-cell Lymphoma is expanding by the approval and launch of upcoming therapies, including the recently approved Seattle'S Adcetris (Brentuximab vedotin).
The market size of Peripheral T-Cell Lymphoma (PTCL) is expected to grow due to increasing incidence as well as awareness among people that it is a treatable condition resulting in increasing diagnosis rate. It is also projected to increase due to rise in its awareness and healthcare expenditure. Additionally, launches of upcoming therapies will also contribute to the overall growth of the market during the forecast period of 2018-2027.
The market of Peripheral T-Cell Lymphoma in 7MM was found to be 203.9 million in 2016, and is expected to increase from 2016-2027.
Peripheral T-Cell Lymphoma (PTCL) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of emerging therapies for Peripheral T-Cell Lymphoma (PTCL), such as Masitinib (AB Science) and others would fuel the growth of the market in the forecast period [2018-2027]. Other emerging drugs in the pipeline of Peripheral T-Cell Lymphoma (PTCL) are also expected to propel the growth of the Peripheral T-Cell Lymphoma (PTCL) market in the upcoming years.
Peripheral T-Cell Lymphoma (PTCL) Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Peripheral T-Cell Lymphoma (PTCL) Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Highly Analyzed Market
- Key Cross Competition
- Treatment Modalities
- Drugs Uptake
Peripheral T-Cell Lymphoma (PTCL) Report Assessment
- Pipeline Product Profiles
- Key Products and Key Players
- Market Drivers and Barriers
- This report will help to develop Business Strategies by understanding the trends shaping and driving Peripheral T-Cell Lymphoma (PTCL) market
- Organize sales and marketing efforts by identifying the best opportunities for Peripheral T-Cell Lymphoma (PTCL) market
- To understand the future market competition in the Peripheral T-Cell Lymphoma (PTCL) market
- Beleodaq (Belinostat): Onxeo S.A.
- Istodax (Romidepsin): Celgene Corporation
- Masitinib: AB Science
- Fenretinide: CerRx
- AB Science
- Celgene Corporation
- Onxeo S.A.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/tjlp2x/global_peripheral?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-peripheral-t-cell-lymphoma-ptcl-report-2018-market-insights-epidemiology-and-market-forecast-2016-2027-featuring-ab-science-celgene-cerrx--onxeo-sa-300771779.html
SOURCE Research and Markets